MX2010003045A - Composiciones de ciclosporina. - Google Patents

Composiciones de ciclosporina.

Info

Publication number
MX2010003045A
MX2010003045A MX2010003045A MX2010003045A MX2010003045A MX 2010003045 A MX2010003045 A MX 2010003045A MX 2010003045 A MX2010003045 A MX 2010003045A MX 2010003045 A MX2010003045 A MX 2010003045A MX 2010003045 A MX2010003045 A MX 2010003045A
Authority
MX
Mexico
Prior art keywords
cyclosporin compositions
compositions
cyclosporin
cyclosporine
disclosed
Prior art date
Application number
MX2010003045A
Other languages
English (en)
Inventor
Walter L Tien
Richard S Graham
Aileen Morgan
Mayssa Attar
Rhett Schiffman
David A Hollander
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2010003045A publication Critical patent/MX2010003045A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente los métodos terapéuticos, las composiciones y los medicamentos relacionados a la ciclosporina.
MX2010003045A 2007-09-20 2008-09-18 Composiciones de ciclosporina. MX2010003045A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/858,200 US20080146497A1 (en) 2006-07-25 2007-09-20 Cyclosporin Compositions
PCT/US2008/076756 WO2009099467A2 (en) 2007-09-20 2008-09-18 Cyclosporin compositions

Publications (1)

Publication Number Publication Date
MX2010003045A true MX2010003045A (es) 2010-04-29

Family

ID=39528114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003045A MX2010003045A (es) 2007-09-20 2008-09-18 Composiciones de ciclosporina.

Country Status (12)

Country Link
US (1) US20080146497A1 (es)
EP (1) EP2190407B1 (es)
JP (1) JP2010540446A (es)
KR (1) KR20100091946A (es)
CN (1) CN101835463A (es)
AU (1) AU2008349774A1 (es)
BR (1) BRPI0816995A2 (es)
CA (1) CA2700182A1 (es)
IL (1) IL204614A0 (es)
MX (1) MX2010003045A (es)
RU (1) RU2010112472A (es)
WO (1) WO2009099467A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20100279951A1 (en) * 2009-05-01 2010-11-04 Aileen Morgan Method of treating allergic conjunctivitis with cyclosporin compositions
US9017725B2 (en) * 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
AU2012351948A1 (en) * 2011-12-16 2014-07-10 Allergan, Inc. Ophthalmic compositions comprising polyvinyl capralactam - polyvinyl acetate - polyethylene glycol graft copolymer
FR2988297B1 (fr) * 2012-03-22 2014-03-28 Thea Lab Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
CA2955037A1 (en) * 2014-07-18 2016-01-21 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
RU2762767C1 (ru) * 2020-09-15 2021-12-22 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Министерства здравоохранения Российской Федерации Способ определения тактильной чувствительности роговицы

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
DE3851152T2 (de) * 1987-09-03 1995-01-26 Univ Georgia Cyclosporin-augenmittel.
ES2098739T3 (es) * 1992-05-13 1997-05-01 Sandoz Ltd Composiciones oftalmicas conteniendo una cyclosporin.
DK2153819T3 (da) * 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
AU2006270041B2 (en) * 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
EP1956906A4 (en) * 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES

Also Published As

Publication number Publication date
CN101835463A (zh) 2010-09-15
KR20100091946A (ko) 2010-08-19
WO2009099467A2 (en) 2009-08-13
AU2008349774A1 (en) 2009-08-13
BRPI0816995A2 (pt) 2015-03-24
IL204614A0 (en) 2010-11-30
CA2700182A1 (en) 2009-08-13
WO2009099467A3 (en) 2009-10-22
RU2010112472A (ru) 2011-10-27
EP2190407A2 (en) 2010-06-02
US20080146497A1 (en) 2008-06-19
EP2190407B1 (en) 2016-12-07
JP2010540446A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
MX2010003045A (es) Composiciones de ciclosporina.
WO2008014200A3 (en) Cyclosporin compositions
WO2010054266A3 (en) Multiblock copolymers
IN2012DN00548A (es)
IN2012DN00746A (es)
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
TN2012000414A1 (en) Forms of rifaximin and uses thereof
ZA200807274B (en) Novel pyridine derivatives
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
TN2011000172A1 (en) Therapeutic antiviral peptides
MX356210B (es) Formulaciones de polimero acrilico.
MX2013000642A (es) Composiciones farmaceuticas.
MY146112A (en) Long-term feed - cancer patient
MX2013004061A (es) Analogos de ciclosporina.
MX2010001865A (es) Composiciones para el cuidado personal que comprenden complejos de colorante-polimero.
MX2010000593A (es) Aumentador del vigor de una planta.
GB2461659A (en) Structured compositions comprising a clay
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
MX2009010689A (es) Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
WO2012061390A3 (en) Therapeutic compositions and methods
MX2013004062A (es) Analogos de ciclosporina.
IN2012DN03404A (es)
TN2009000135A1 (en) Use of modified cyclosporins

Legal Events

Date Code Title Description
FA Abandonment or withdrawal